Voya Investment Management LLC Has $19.03 Million Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Voya Investment Management LLC raised its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 13.3% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 139,441 shares of the company's stock after buying an additional 16,373 shares during the period. Voya Investment Management LLC owned about 0.14% of Neurocrine Biosciences worth $19,034,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of NBIX. Dodge & Cox grew its stake in Neurocrine Biosciences by 134.2% in the fourth quarter. Dodge & Cox now owns 3,016,425 shares of the company's stock valued at $411,742,000 after purchasing an additional 1,728,605 shares in the last quarter. Raymond James Financial Inc. acquired a new stake in shares of Neurocrine Biosciences during the 4th quarter valued at about $115,193,000. Wellington Management Group LLP grew its stake in shares of Neurocrine Biosciences by 102.9% in the 4th quarter. Wellington Management Group LLP now owns 1,457,425 shares of the company's stock valued at $198,939,000 after buying an additional 739,199 shares in the last quarter. Thrivent Financial for Lutherans increased its holdings in Neurocrine Biosciences by 2,759.4% in the fourth quarter. Thrivent Financial for Lutherans now owns 737,772 shares of the company's stock worth $100,705,000 after buying an additional 711,970 shares during the last quarter. Finally, Jennison Associates LLC raised its position in Neurocrine Biosciences by 145.1% during the fourth quarter. Jennison Associates LLC now owns 820,694 shares of the company's stock valued at $112,025,000 after acquiring an additional 485,894 shares in the last quarter. 92.59% of the stock is currently owned by hedge funds and other institutional investors.

Neurocrine Biosciences Trading Up 0.4 %

NBIX stock traded up $0.45 during midday trading on Wednesday, hitting $107.69. The stock had a trading volume of 1,267,006 shares, compared to its average volume of 1,070,275. Neurocrine Biosciences, Inc. has a 52 week low of $84.23 and a 52 week high of $157.98. The stock has a 50-day simple moving average of $106.82 and a 200 day simple moving average of $122.06. The firm has a market capitalization of $10.65 billion, a price-to-earnings ratio of 32.73, a P/E/G ratio of 0.77 and a beta of 0.33.

Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) last issued its earnings results on Thursday, February 6th. The company reported $1.00 earnings per share for the quarter, missing the consensus estimate of $1.62 by ($0.62). Neurocrine Biosciences had a net margin of 14.49% and a return on equity of 13.38%. On average, equities analysts forecast that Neurocrine Biosciences, Inc. will post 4.28 EPS for the current year.

Neurocrine Biosciences declared that its board has approved a share repurchase program on Friday, February 21st that allows the company to repurchase $500.00 million in outstanding shares. This repurchase authorization allows the company to buy up to 4.2% of its shares through open market purchases. Shares repurchase programs are usually an indication that the company's board believes its shares are undervalued.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on NBIX shares. Deutsche Bank Aktiengesellschaft assumed coverage on shares of Neurocrine Biosciences in a research note on Tuesday, February 11th. They set a "hold" rating and a $138.00 price target on the stock. Bank of America cut their target price on Neurocrine Biosciences from $184.00 to $179.00 and set a "buy" rating on the stock in a report on Friday, February 7th. JPMorgan Chase & Co. upped their price target on Neurocrine Biosciences from $183.00 to $184.00 and gave the stock an "overweight" rating in a research note on Wednesday, March 26th. Canaccord Genuity Group cut their price objective on Neurocrine Biosciences from $163.00 to $158.00 and set a "buy" rating on the stock in a research note on Monday. Finally, Royal Bank of Canada raised Neurocrine Biosciences from a "sector perform" rating to an "outperform" rating and decreased their target price for the stock from $138.00 to $137.00 in a research report on Monday, April 14th. Three research analysts have rated the stock with a hold rating and twenty have given a buy rating to the company's stock. According to MarketBeat.com, Neurocrine Biosciences presently has a consensus rating of "Moderate Buy" and a consensus target price of $160.90.

Insider Buying and Selling at Neurocrine Biosciences

In other Neurocrine Biosciences news, insider Julie Cooke sold 1,740 shares of the company's stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $152.89, for a total transaction of $266,028.60. Following the sale, the insider now directly owns 18,202 shares of the company's stock, valued at approximately $2,782,903.78. This represents a 8.73 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Kevin Charles Gorman sold 5,844 shares of Neurocrine Biosciences stock in a transaction that occurred on Thursday, February 13th. The shares were sold at an average price of $116.69, for a total transaction of $681,936.36. Following the completion of the transaction, the director now owns 521,618 shares of the company's stock, valued at $60,867,604.42. This trade represents a 1.11 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 21,801 shares of company stock valued at $2,834,677. 4.30% of the stock is currently owned by corporate insiders.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.